Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Apixaban via NGT with Boost Plus or as Crushed Tablet
NCT02034591Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2011
- Primary completion
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of apixaban in thromboembolism (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum Observed Plasma Concentration at 72 hours, Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time at 72 hours and 1 more. Started Oct 2011; status: completed.
02
Drugs
apixaban
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT02034591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02034591.